Compare ThredUp Inc (TDUP) vs Tango Therapeutics Inc. (TNGX) Price & Performance

ThredUp (TDUP) trades at $2.2, down 11.29% in the last session, with a bullish technical signal from moving averages but mixed oscillators. The company reported record Q2 2026 revenue of $90.8 million, up 17% year-over-year, but missed EPS estimates and cut full-year revenue guidance. Cash flow from operations improved to $10.65 million in 2025, though net income remains negative. Analyst consensus is 57% buy, with no sell ratings, but recent news highlights promotional headwinds and a securities investigation.

The outlook is cautious; revenue growth and high gross margins are positives, but persistent losses, weak guidance, and legal risks pose challenges. The stock's low price-to-sales ratio of 0.88 may attract value investors, yet profitability concerns and negative ROE of -36.76% underscore significant execution risk. Investors should weigh strong analyst support against fundamental weaknesses and market sentiment shifts.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.